$1.5 Billion Pharma Buyout for Leukemia Drug

By Jef Akst | June 1, 2016

acute myeloid leukemiaAcute myeloid leukemiaWIKIMEDIA, AFIPDublin, Ireland–based Jazz Pharmaceuticals will purchase Celator Pharmaceuticals, headquartered in New Jersey, for $1.5 billion, Reuters reported. Celator’s investigational new drug called Vyxeos, indicated for the treatment of a rare blood disorder called acute myeloid leukemia (AML), has received orphan-drug status in the U.S. and Europe and in May was named a breakthrough therapy by the US Food and Drug Administration. Late-stage trial results released in March pointed to the treatment’s ability to increase life span in older, high-risk AML patients.

“As Celator is currently preparing a regulatory submission in the U.S. for Vyxeos, this acquisition would add a new orphan product with the potential for short- and long-term revenue generation and expansion of our international commercial platform,” Jazz Pharmaceuticals Chief Executive Bruce Cozadd said in a statement.

Celator is “a very good strategic fit” for Jazz, Stephen Willey, an analyst with Stifel Nicolaus & Co., wrote in a note to investors, according to Bloomberg.

(Hat tip: GEN)

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: Jason Price

Jason Price

Posts: 2

July 30, 2016

Thats crazy money!!

Popular Now

  1. Could Rapamycin Help Humans Live Longer?
  2. Renowned Physicist Stephen Hawking Dies
  3. Pupil Response to an Optical Illusion Tied to Autistic Traits
  4. John Sulston, Human Genome Project Leader, Dies